Gopten

Gopten is a prescription medication that contains the active ingredient trandolapril, an ACE inhibitor, supplied in an oral dosage form; the specific strength is not disclosed in the available product information. It is marketed in the European Union and is classified as a prescription‑only drug. It belongs to the therapeutic class of antihypertensives and is used under medical supervision to manage cardiovascular conditions in adult patients.

Gopten (trandolapril) is indicated for the oral treatment of several cardiovascular disorders.

- Management of essential hypertension. - Treatment of chronic heart failure to improve symptoms and reduce hospitalizations. - Post‑myocardial infarction therapy to attenuate ventricular remodeling. - Adjunctive therapy in patients with diabetic nephropathy when prescribed by a specialist.

The safety profile of trandolapril includes both frequently observed and less common adverse events.

Common: - Persistent dry cough. - Dizziness or light‑headedness, especially after the first dose. - Headache. - Fatigue or mild weakness. - Transient hypotension. - Elevated blood potassium levels.

Serious: - Angioedema involving the face, lips, tongue, or airway. - Severe or symptomatic hypotension. - Acute renal failure or significant rise in serum creatinine. - Neutropenia or agranulocytosis. - Hepatotoxicity presenting as jaundice or elevated liver enzymes. - Hyperkalemia leading to cardiac arrhythmias.

Before initiating Gopten, clinicians should evaluate several clinical factors to minimize risk.

- Assess renal function and adjust dose in patients with moderate to severe impairment. - Monitor serum potassium and avoid use in patients with hyperkalemia. - Use with caution in patients with a history of angioedema related to ACE inhibitors. - Contraindicated during the second and third trimesters of pregnancy (Category D). - Review concomitant use of potassium‑sparing diuretics or supplements. - Advise patients to rise slowly from sitting or lying positions to reduce orthostatic dizziness. - Periodic liver function tests are recommended for long‑term therapy.

Trandolapril may interact with several medication classes, influencing its efficacy or safety.

Avoid: - Concurrent use with other ACE inhibitors, ARBs, or aliskiren in diabetic patients. - Combination with potassium‑sparing diuretics or high‑dose potassium supplements. - Use with non‑steroidal anti‑inflammatory drugs (NSAIDs) that may impair renal function.

Use with caution: - Dual therapy with diuretics may increase the risk of hypotension. - Concomitant lithium therapy may raise lithium levels. - Co‑administration with certain antidiabetic agents may require glucose monitoring. - Interaction with rifampin or other enzyme inducers may reduce trandolapril plasma concentrations.